[1] Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J. Incidence and late prognosis of cushing's syndrome:a population-based study[J]. J Clin Endocrinol Metab, 2001, 86:117-123.
[2] Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing's disease:the state of the art[J]. Endocrine, 2014, 47:9-20.
[3] Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients < 65 years old in the United States[J]. Pituitary, 2015, 18:283-289.
[4] Yamazaki M, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, Imai T, Kaji H, Komoto I, Miura D, Yamada M, Uruno T, Horiuchi K, Sato A, Miyauchi A, Imamura M, Sakurai A; MEN Consortium of Japan. Delay in the diagnosis of multiple endocrine neoplasia type 1:typical symptoms are frequently overlooked[J]. Endocr J, 2012, 59:797-807.
[5] Castinetti F, Qi XP, Walz MK, Maia AL, Sansó G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA, Mian C, Bugalho MJ, Wohllk N, Kollyukh O, Canu L, Loli P, Bergmann SR, Biarnes Costa J, Makay O, Patocs A, Pfeifer M, Shah NS, Cuny T, Brauckhoff M, Bausch B, von Dobschuetz E, Letizia C, Barczynski M, Alevizaki MK, Czetwertynska M, Ugurlu MU, Valk G, Plukker JT, Sartorato P, Siqueira DR, Barontini M, Szperl M, Jarzab B, Verbeek HH, Zelinka T, Vlcek P, Toledo SP, Coutinho FL, Mannelli M, Recasens M, Demarquet L, Petramala L, Yaremchuk S, Zabolotnyi D, Schiavi F, Opocher G, Racz K, Januszewicz A, Weryha G, Henry JF, Brue T, Conte-Devolx B, Eng C, Neumann HP. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2:an international retrospective population-based study[J]. Lancet Oncol, 2014, 15:648-655.
[6] Thakker RV. Multiple endocrine neoplasia type 1(MEN1) and type 4(MEN4)[J]. Mol Cell Endocrinol, 2014, 386:2-15.
[7] Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Treatment of Cushing's syndrome:an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2015, 100:2807-2831.
[8] Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1(MEN1)[J]. J Clin Endocrinol Metab, 2012, 97:2990-3011.
[9] Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of Cushing's syndrome[J]. Neuroendocrinology, 2010, 92 Suppl 1:1-5.
[10] Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV. Clinical studies of multiple endocrine neoplasia type 1(MEN1)[J]. QJM, 1996, 89:653-669.
[11] McDonnell JE, Gild ML, Clifton-Bligh RJ, Robinson BG. Multiple endocrine neoplasia:an update[J]. Intern Med J, 2019, 49:954-961.
[12] Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ. Williams textbook of endocrinology 14th edition[M]. Amsterdam:Elsevier, 2019:298-299.
[13] Simonds WF, Varghese S, Marx SJ, Nieman LK. Cushing's syndrome in multiple endocrine neoplasia type 1[J]. Clin Endocrinol (Oxf), 2012, 76:379-386.
[14] Chiodini I, Albani A, Ambrogio AG, Campo M, De Martino MC, Marcelli G, Morelli V, Zampetti B, Colao A, Pivonello R; ABC Group. Six controversial issues on subclinical Cushing's syndrome[J]. Endocrine, 2017, 56:262-266.
[15] Mazzuco TL, Bourdeau I, Lacroix A. Adrenal incidentalomas and subclinical Cushing's syndrome:diagnosis and treatment[J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16:203-210.
[16] Tamada D, Kitamura T, Otsuki M, Oshino S, Saitoh Y, Shimomura I. Clinical significance of screening for subclinical Cushing's disease in patients with pituitary tumors[J]. Endocr J, 2016, 63:47-52.
[17] Teh BT, Zedenius J, Kytölä S, Skogseid B, Trotter J, Choplin H, Twigg S, Farnebo F, Giraud S, Cameron D, Robinson B, Calender A, Larsson C, Salmela P. Thymic carcinoids in multiple endocrine neoplasia type 1[J]. Ann Surg, 1998, 228:99-105.
[18] Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N, Daddi G, Puma F, Ribacchi R, Santeusanio F, Angeletti G, Brandi ML. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome:the Italian series[J]. J Clin Endocrinol Metab, 2005, 90:2603-2609.
[19] Ghazi AA, Dezfooli AA, Mohamadi F, Yousefi SV, Amirbaigloo A, Ghazi S, Pourafkari M, Berney D, Ellard S, Grossman AB. Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1[J]. Endocr Pract, 2011, 17:e92-96.
[20] Norton JA, Krampitz G, Jensen RT. Multiple endocrine neoplasia:genetics and clinical management[J]. Surg Oncol Clin N Am, 2015, 24:795-832.
[21] Al-Salameh A, Baudry C, Cohen R. Update on multiple endocrine neoplasia type 1 and 2[J]. Presse Med, 2018, 47:722-731.
[22] Buliman A, Tataranu LG, Paun DL, Mirica A, Dumitrache C. Cushing's disease:a multidisciplinary overview of the clinical features, diagnosis, and treatment[J]. J Med Life, 2016, 9:12-18.
[23] Valle Díaz de la Guardia F, Arrabal Martín M, Arrabal Polo MA, Quirosa Flores S, Miján Ortiz JL, Zuluaga Gómez A. Renal lithiasis in patients with primary hyperparathyroidism:evolution and treatment[J]. Arch Esp Urol, 2010, 63:32-40. |